MMP13-IN-2 |
| Katalog-Nr.GC65957 |
MMP13-IN-2 ist ein potenter, selektiver und oral aktiver MMP-13-Inhibitor. MMP13-IN-2 weist eine hervorragende Wirksamkeit fÜr MMP-13 (IC50 = 0,036 nM) und SelektivitÄten (mehr als 1.500-fach) gegenÜber MMP-1, 3, 7, 8, 9, 14 und TACE auf. MMP13-IN-2 hat die FÄhigkeit, die Freisetzung von Kollagen aus Knorpel in vitro zu blockieren. MMP13-IN-2 hat das Potenzial fÜr die Erforschung von Krankheiten im Zusammenhang mit Kollagenase.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 935759-55-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MMP13-IN-2 is a potent, selective and orally active MMP-13 inhibitor. MMP13-IN-2 exhibits excellent potency for MMP-13 (IC50=0.036 nM) and selectivities (greater than 1,500-fold) over MMP-1, 3, 7, 8, 9, 14, and TACE. MMP13-IN-2 has the ability to block the release of collagen from cartilage in vitro. MMP13-IN-2 has the potential for collagenase related disease research[1].
In a bovine nasal cartilage (BNC) assay, the chondrocyte-mediated degradation of cartilage was studied using bovine nasal cartilage slices cultured for up to 14 days. MMP13-IN-2 (0.01-1 µM) is effective at preventing the IL-1/OSM induced in vitro degradation of BNC (-17.6%, 48.4% and 70.8% inhibition of cartilage degradation, respectively).[1].
MMP13-IN-2 (oral gavage; 1 mg/kg) shows the best combination of CYP3A4 inhibition risk and oral exposure at a dose of 1 mg/kg in rats and mice (F% = 33 and 38, respectively)[1].
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *